CAS: 6384-92-5; (R)-2-(Methylamino)Succinic Acid

上下游产品

CAS号17833-53-3 甲基天冬氨酸 | CAS号144300-47-0 N-methylasparti... | CAS号1783-96-6 D-天门冬氨酸 | CAS号74-88-4 碘甲烷 | CAS号1010433-25-6 Grassypeptolide A | CAS号77-78-1 硫酸二甲酯

(+/-)-N-Formyl-N-Methyl-Asparaginsaeure置于双氧水体系中,化学反应生成 N-甲基-D-天冬氨酸
参考文献:54岁的化学最好的免疫学.lytergsäure的化学.mitteilungübermutterkornalkaloide
标题:54岁的化学最好的免疫学.lytergsäure的化学.mitteilungübermutterkornalkaloide
摘要:通过将6-甲基-8-亚甲基-7-酮-麦角戊烯进行臭氧化,然后用过甲酸氧化成dn-甲基-天冬氨酸,确定了天然麦角酸的绝对构型为(5 R:8 R).二正丙基酯的形式
DOI:10.1002/hlca.19620450636

专利信息

专利号:US-2025049961-A1
优先权日:2021-12-23
标题 :Scalable and high-purity cell-free synthesis of closed-ended dna vectors
发明人：MONDS RUSSELL; CIPI JORIS; BLACKSTOCK DANIEL JASON; DURANT JOHN CHESTER
权利人:GENERATION BIO CO
摘要:This disclosure provides methods for scalable and high-purity cell-free synthesis of DNA vectors, particularly closed-ended DNA vectors (e.g., ceDNA vectors) having linear and continuous structure for delivery and expression of a transgene. The cell-free synthesis includes digesting a double-stranded DNA construct with at least one restriction endonuclease that is capable of cleaving the construct at cleavage sites, which are distinct from the recognition sites, to release an insert having unique overhangs that regulate the high specificity of the subsequent ligation reaction. The insert is then ligated with inverted terminal repeat (ITR) oligonucleotides to form the closed-ended DNA vector. Corresponding DNA vectors prepared by these methods and related products as well other base and intermediate vectors and constructs associated with the methods are also provided in this disclosure.

专利号:US-2016031800-A1
优先权日:2013-03-14
标 题:Synthesis of chiral kynurenine compounds and intermediates
发明人：TRETYAKOV ALEXANDER; DROUET KEITH E; SANDERS WILLIAM
权利人:VISTAGEN THERAPEUTICS INC
摘要:Provided are methods for the synthesis of compounds including chiral kynurenine compounds, intermediates useful for the synthesis thereof, and related compounds. For example, methods are provided for the synthesis of L-4-chlorokynurenine.

专利号:US-11427530-B2
优先权日:2018-02-09
标 题 :Synthesis of 4-chlorokynurenines and intermediates
发明人：LEVIN DANIEL; LEEMING PETER; EISENREICH EMERICH; LIU XUEJUN KARL
权利人:VISTAGEN THERAPEUTICS INC
摘要:The invention relates to an overall enantio-specific synthesis of 4-chlorokynurenine compounds, in particular L-4-chlorokynurenine, with improved yields. Large-scale syntheses are disclosed. The invention also relates to novel intermediates in the synthesis of L-4-chlorokynurenine.

专利号:US-5338851-A
优先权日:1993-03-31
标 题:Synthesis of cis-decahydroisoquinoline-3-carboxylic acids
发明人：HUFF BRET E; KHAU VIEN V; MARTINELLI MICHAEL J; PETERSON BARRY C
权利人:LILLY CO ELI
摘要:This invention provides a process for the synthesis of cis-decahydroisoquinoline-3-carboxylic acids and provides intermediates in the synthesis thereof.

专利号:US-6271379-B1
优先权日:2000-03-08
标题:Intermediates useful for the synthesis of huperzine A
发明人：TUECKMANTEL WERNER; KOZIKOWSKI ALAN P
权利人:UNIV GEORGETOWN
摘要:Intermediates useful for the synthesis of huperzine A represented by the structures below, n and methods for their synthesis, wherein: n R 1 is lower alkyl, benzyl, or substituted benzyl; n X is a suitable leaving group; n Y is an electron withdrawing group that can subsequently be converted into an amino group; n one broken line is present as a carbon—carbon bond and the other broken line is absent, where the broken line forms an unconjugated carbon—carbon double bond, which double bond may be endocyclic whereby n is 3 or the double bond may be exocyclic whereby n is 2.

专利号:US-9085518-B2
优先权日:2011-10-14
标题 :Method for the synthesis of 18F-labelled molecules
发明人：NAIRNE ROBERT JAMES DOMETT; BHALLA RAJIV; KHAN IMTIAZ; BROWN JANE; WILSON ANTHONY; BLACK ANDRES
权利人:GE HEALTHCARE LTD
摘要:The present invention provides a method for the synthesis of 18F-labelled biomolecules, which is amenable to automation. The present invention also provides a cassette for automating the method of the invention. The method of the present invention provides numerous advantages over the prior art methods. One less purification step is required as compared with known methods. Also, in a preferred embodiment, one less reagent is required as a particular reagent is employed in two different steps. The chemistry process is thereby simplified, the cost of goods is reduced and the burden of validation and documentation of reagents required for GMP clinical production is minimized.